Annexin Pharmaceuticals Future Growth
Future criteria checks 2/6
Annexin Pharmaceuticals is forecast to grow earnings and revenue by 46.9% and 178.1% per annum respectively.
Key information
46.9%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 48.1% |
| Revenue growth rate | 178.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 40 | -17 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -52 | N/A | N/A | 1 |
| 3/31/2024 | N/A | -46 | -45 | -45 | N/A |
| 12/31/2023 | N/A | -44 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -40 | -43 | -43 | N/A |
| 6/30/2023 | N/A | -38 | -40 | -40 | N/A |
| 3/31/2023 | N/A | -41 | -43 | -43 | N/A |
| 12/31/2022 | N/A | -41 | -41 | -41 | N/A |
| 9/30/2022 | N/A | -47 | -39 | -39 | N/A |
| 6/30/2022 | N/A | -45 | -39 | -39 | N/A |
| 3/31/2022 | N/A | -43 | -40 | -40 | N/A |
| 12/31/2021 | N/A | -52 | -45 | -45 | N/A |
| 9/30/2021 | N/A | -53 | -47 | -47 | N/A |
| 6/30/2021 | N/A | -53 | -48 | -48 | N/A |
| 3/31/2021 | N/A | -55 | -48 | -48 | N/A |
| 12/31/2020 | N/A | -44 | -39 | -39 | N/A |
| 9/30/2020 | N/A | -38 | -34 | -34 | N/A |
| 6/30/2020 | N/A | -36 | -30 | -30 | N/A |
| 3/31/2020 | N/A | -31 | -24 | -24 | N/A |
| 12/31/2019 | N/A | -28 | -26 | -26 | N/A |
| 9/30/2019 | N/A | -25 | -24 | -24 | N/A |
| 6/30/2019 | N/A | -24 | -26 | -26 | N/A |
| 3/31/2019 | N/A | -25 | -27 | -27 | N/A |
| 12/31/2018 | N/A | -29 | -29 | -29 | N/A |
| 9/30/2018 | N/A | -31 | -33 | -33 | N/A |
| 6/30/2018 | N/A | -30 | -36 | -35 | N/A |
| 3/31/2018 | N/A | -32 | -39 | -39 | N/A |
| 12/31/2017 | N/A | -31 | N/A | -39 | N/A |
| 9/30/2017 | N/A | -25 | N/A | -36 | N/A |
| 6/30/2017 | N/A | -26 | N/A | -29 | N/A |
| 3/31/2017 | N/A | -17 | N/A | -18 | N/A |
| 12/31/2016 | N/A | -10 | N/A | -10 | N/A |
| 12/31/2015 | N/A | -5 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ANNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ANNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ANNX's revenue (178.1% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: ANNX's revenue (178.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANNX's Return on Equity is forecast to be high in 3 years time